|
The Application of Antiangiogenesis Drug in the Experiment of Interventional Therapy of Hepatocellular Carcinoma<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
钱骏* 徐才元* 冯敢生*
Vossoughi Daryusch＃
Oppermann Elsie＃
Thomas Vogl＃
＊华中科技大学同济医学院附属协和医院放射科,武汉 430022
＃法兰克福，Department of Diagnostic and Interventional Radiology, Frankfurt University Hospital, Germany
ABSTRACT
Purpose: To assess the value of combination of transarterial chemoembolization (TACE) and transarterial administration of TNP-470 and Endostatin as antiangiogenesis drugs for treating hepatocellular carcinoma (HCC) in ACI rats.
Materials and Methods: A solid Morris Hepatoma 3924A (2 mm3) was implanted into the liver of 30 male ACI rats. After laparotomy and retrograde placement of a microcatheter into the gastroduodenal artery, the following agents were injected into the hepatic artery (14 days after implantation): (A) Mitomycin (0.1 mg) ( Lipiodol (0.1 ml) ( TNP-470 (5.0 mg) (n=10); (B) Mitomycin (0.1 mg) ( Lipiodol (0.1 ml) ( Endostatin (0.4 mg) (n=10); (C) Mitomycin (0.1 mg) ( Lipiodol (0.1 ml) (n=10, control group). The tumor volumes before treatment (V1) and after treatment (V2) were determined by MRI and the tumor growth ratio (V2/V1) was calculated.
Results: The mean tumor volume V1 and V2 were 0.04 cm3 and 0.15 cm3 in group A, 0.04 cm3 and 0.25 cm3 in group B, 0.04 cm3 and 0.34 cm3 in group C, respectively. After interventional therapy, the resulting mean ratio of V2/V1 is 4.11 in group A, 7.78 in group B and 9.14 in group C, respectively. Compared with the group B (control group), group A showed very significant inhibition of tumor growth within the period of observation (P<0.01), but group B did not (P>0.01).
Conclusion: The growth of HCC can be obviously reduced by utilizing the combined TACE and transadministration of TNP-470 for treating HCC in ACI rats.
Key Words: Carcinoma, Hepatocellular; Therapy, Interventional; TNP-470; Endostatin |
